While Large/Mid Cap Biotechnology companies are boasting rising profitability, better cash flows, and stronger drug pipelines, the Small/Micro Cap Biotech firms, in general, have little tangible to show and valuations may be above the comfort zone.
May
08
2015
Small Cap Biotech Valuations: Proceed With Caution
Login
For full access, please enter your credentials.
Not a Subscriber?
If you are interested in subscribing to The Leuthold Group, contact us online or give us a call at 612-332-1567.
Contact UsAbout The Author
current issue
featured articles
recent tags
Bank Lending
(1)
Wealth Effect
(9)
Resession
(1)
Dollar
(55)
Inflation
(584)
Time Cycles
(6)
Oil
(48)
Breakeven Rate
(1)
Value
(130)
Treasuries
(79)
Long T-Bonds
(24)
Active vs. Passive
(17)
Yield Curve
(85)
Economy
(282)
Federal Spending
(2)
Stock Market Performance
(1)
Federal Debt/Deficit
(194)
Fed Policy
(173)
Federal Outlays
(1)
Stimulus
(4)